This Amendment No. 1 (Amendment No. 1) to Schedule 13D relates to
the Class A Common Stock, par value $0.0001 per share (the Class A Shares), of MSP Recovery, Inc., a Delaware corporation (the Issuer), and amends and supplements the initial statement on
Schedule 13D filed by Cano Health, Inc., a Delaware corporation (the Reporting Person), with the Securities and Exchange Commission on July 17, 2023 (as so amended, the Schedule 13D). Capitalized terms used
but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D.
Item 2. Identity and Background.
Item 2 of the Schedule 13D is hereby amended by incorporating herein by reference the information set forth on the updated Annex
A attached hereto.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended and restated as follows:
The Reporting Persons acquired the Class A Shares for investment purposes as described herein.
The Reporting Person intends to review its position in the Issuer on an ongoing basis and may from time to time increase or decrease its
position in the Issuer (including through the trading of derivatives) depending upon various factors, including but not limited to, the Issuers business and prospects, financial position and strategic direction, price levels of the
Class A Shares, conditions in the securities markets, various laws and regulations applicable to the Reporting Person, the Issuer and companies in its industry, the Reporting Persons ownership in the Issuer, other investment and business
opportunities available to the Reporting Person and general economic and industry conditions, and tax considerations. Additionally, subject to the various factors described above, the Reporting Person may in the future take any other action with
respect to its position in the Issuer as it deems appropriate, including communicating with the Issuers board of directors (the Board), members of management or other Issuer stockholders from time to time, and/or take any
other available course of action, which could involve one or more of the types of transactions or have one or more of the results described in clauses (a) through (j) of the instructions to Item 4 of Schedule 13D. Notwithstanding the above, the
Reporting Person currently intends to continue to sell its Class A Shares from time to time in open market transactions, block sales, in privately negotiated transactions or otherwise, provided that the Reporting Person may modify this
intention at any time and from time to time.
Except as described in this Schedule 13D, the Reporting Person does not have any present
plans or proposals that relate to or would result in any of the actions described in Item 4 of this Schedule 13D, although, the Reporting Person, at any time and from time to time, may review, reconsider and change their position and/or purpose
and/or develop such plans and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.
Item 5. Interest in Securities of the Issuer.
Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:
(a) and (b) The percentage of beneficial ownership of the Class A Shares reported in this Schedule 13D assumes 14,415,930
Class A Shares outstanding as of November 27, 2023, based on information set forth in the Form S-1/A filed by the Issuer on December 8, 2023 (the Form
S-1/A).
As of January 11, 2024, the aggregate number and percentage of
Class A Shares beneficially owned by the Reporting Person and, for the Reporting Person, the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to
direct the disposition, or shared power to dispose or to direct the disposition are set forth on rows 7 through 11 and row 13 of the cover page of this Schedule 13D and are incorporated herein by reference. The beneficial ownership reported herein
reflects the Issuers 1-for-25 reverse stock split of its Class A Shares effective as of October 13, 2023.
As of January 11, 2024, Cano Health, LLC, an indirect subsidiary of the Reporting Person, directly owns the 7,809,039 Class A Shares
reported herein representing approximately 54.2% of the Class A Shares outstanding.